Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Malignant Neoplasm
100%
Hospitalist
98%
Immune Checkpoint Inhibitor
65%
Venous Thromboembolism
61%
Immune-Related Adverse Events
60%
Lung
57%
Anticoagulation
54%
COVID-19
49%
Pneumonia
49%
Bleeding
49%
Oncology
49%
Prospective Cohort Study
49%
Thrombosis
49%
Cancer Recurrence
49%
Adverse Event
49%
Immunotherapy
49%
Medicine
49%
Solid Malignant Neoplasm
49%
Anticoagulant Therapy
36%
Low Molecular Weight Heparin
29%
Direct Oral Anticoagulant
29%
Major Bleeding
24%
Cancer
17%
Inferior Vena Cava Filter
17%
Lung Cancer
12%
Shared Decision Making
12%
Prothrombin Complex
12%
Protamine
12%
Prevalence
12%
Andexanet Alfa
12%
Idarucizumab
12%
Fresh Frozen Plasma
12%
Severe Acute Respiratory Syndrome Coronavirus 2
8%
Infection
8%
Post-COVID-19
8%
Myocarditis
8%
Colitis
8%
Hospital Medicine
8%
Pembrolizumab
8%
Thoracic Cancer
8%
Neoplasm
8%
Respiratory Medicine
7%
Clinician
7%
Keyphrases
Recurrent Cancer
49%
Recurrent Venous Thromboembolism
49%
Risk Management
49%
Risk Diagnosis
49%
Cancer-associated Thrombosis
49%
Narrative Review
49%
Hospital-Based Clinical Medicine
49%
Sleeping Disease
49%
Venous Thromboembolism
32%
In Cancer
16%
Critical Bleeding
16%
Bleeding Risk Score
16%
Direct Oral Anticoagulants
8%
Cancer Patients
8%
Genitourinary Cancer
8%
Low Molecular Weight Heparin
8%
Thrombogenesis
8%
Inferior Vena Cava Filter
8%
Major Risk Factors
8%
Laboratory Data
8%
Policy Control
8%
Vitamin K Antagonists
8%
Imaging Results
8%
Oral Anticoagulation
8%
Lung Cancer
8%
Colorectal Cancer
8%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
56%
Solid Malignant Neoplasm
55%
Adverse Event
49%
Immunotherapy
49%
Glucagon Like Peptide 1 Receptor Agonist
49%
Metabolic Disorder
49%
Glucagon-Like Peptide-1
32%
Diseases
20%
Maturity Onset Diabetes of the Young
16%
Immune Checkpoint Inhibitor
14%
Sleep Disordered Breathing
8%
Liraglutide
8%
Chronotherapy
8%
Glucagon-Like Peptide 1 Receptor
8%
Tirzepatide
8%
Semaglutide
8%
Incretin
8%
Pharmacokinetic
8%
Colitis
7%
Myocarditis
7%
Pembrolizumab
7%
Neoplasm
7%
Public Health Policy
6%
Infection
6%
Hematologic Malignancy
6%
Overall Survival
6%